Cybin Inc. Common Stock
$6.80-1.2%YTD-16.8%1Y+16.4%
Mentions · last 7 days
108+5%
Price updated 12m ago·X counts updated 2d ago
Sentiment on XAI analysisGenerated by AI from underlying data
How loud the X conversation is around $HELP and which way it's leaning — read in seconds.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $HELP.
Biotechnology
GLP-1 pipeline competition is the dominant structural driver — the ADA conference crystallized oral formulations, dual agonists, and differentiated mechanisms competing for a potential $150B obesity market by 2030. QURE's FDA accelerated approval for AMT-130 (Huntington's disease) this week confirms gene therapy regulatory momentum is still flowing capital to non-GLP-1 precision medicine.
Top industry ETF
$IBBiShares Biotechnology ETF
+11.9%YTD
+50.0%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-1.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-44.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-72.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
-61.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q4 2025Feb 13, 2026$-0.72$-0.53-35.8%
Q3 2025Nov 13, 2025$-1.39$-0.74-87.8%
Q2 2025Aug 13, 2025$-1.10$-0.96-14.7%
Q2 2025Jul 1, 2025$-1.01$-0.85-18.7%
Next earningsThu, Aug 6·consensus EPS $-0.84
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q3 FY26$0———$-1.76$-32.3M
Q2 FY26$0———$-1.94$-48.7M
Q1 FY26$0———$-1.10$-21.9M
Q4 FY25$0———$-1.46$-22.2M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$0$0 – $0-$4.03-$4.48 – -$3.590
FY27$31.7M$31.7M – $31.7M-$2.87-$3.15 – -$2.583
FY28$26.2M$26.2M – $26.2M-$2.07-$2.41 – -$1.315
FY29$404.0M$404.0M – $404.0M$0.40-$0.57 – $2.405
FY30$823.9M$823.9M – $823.9M$3.03$3.03 – $3.032
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.—Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+40.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.—Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatLow float · 39.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today4.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.705-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
No material 8-K / SC 13D / S-3 / 424B5 filings in the last 180 days.
+ 36 other (21 6-Ks · 8 13Gs · 2 Ds · 1 40-F) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial ResultsCybin: A Speculative Bet On Their Pivotal Depression ReadoutA Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This YearHelus Pharma™ Announces Closing of US$50 Million Underwritten OfferingHelus Pharma™ Announces Closing of US$50 Million Underwritten Offering
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · top 5 · last 7 days